In addition to surgical resection of the tumour, conventional radio- and chemotherapy for cancer treatment, the use of sTRAIL or other agonists, and inhibiting NF-κB signalling has potential therapeutic applications for cancer therapy. This evidence concerns the gene NFKB1 and neoplasm.